Limits...
Efficacy and Tolerability of Steroid-Free, Over-the-Counter Treatment Formulations in Infants and Children With Atopic Dermatitis.

Weber TM, Herndon JH, Ewer M, Stephens TJ, Flick I, Filbry A, Neufang G, Schoelermann AM - J Dermatol Nurses Assoc (2015)

Bottom Line: Body Cream significantly improved skin hydration and reduced itching, burning/stinging, erythema, and tactile roughness.Both products were safe and well tolerated.These products provide steroid-free, nonprescription therapy for the maintenance and treatment of acute eczema and were proven effective and safe in infants as young as 3 months.

View Article: PubMed Central - PubMed

Affiliation: Teresa M. Weber, PhD, U.S. Research and Development, Beiersdorf, Inc., Wilton, CT.

ABSTRACT

Background: Two steroid-free, over-the-counter skin protectant products have been developed for the care and treatment of atopic dermatitis (AD)-Eucerin Eczema Relief Body Crème (Body Cream) for daily skin moisturization and Eucerin Eczema Relief Instant Therapy cream (Instant Therapy) for treatment of AD flare-ups. We tested the efficacy and tolerability of these formulations in infants and children with AD.

Methods: Study 1: Body Cream was applied twice daily to the lower legs of 64 children with a history of AD (aged 3 months to 12 years) for 14 days. Study 2: Instant Therapy was applied to active lesions and surrounding skin of 29 children (aged 3 months to 12 years) with active atopic lesions. Assessments were performed at baseline and Days 7 and 14. Symptoms were assessed using the Atopic Dermatitis Severity Index in Study 2.

Results: Body Cream significantly improved skin hydration and reduced itching, burning/stinging, erythema, and tactile roughness. Instant Therapy significantly improved skin hydration and AD symptoms, notably pruritus, erythema, and lichenification. Both products were safe and well tolerated.

Discussion: Body Cream and Instant Therapy were effective and well tolerated in the treatment of AD in children. These products provide steroid-free, nonprescription therapy for the maintenance and treatment of acute eczema and were proven effective and safe in infants as young as 3 months.

No MeSH data available.


Related in: MedlinePlus

Improvement in Atopic Dermatitis Severity Index (ADSI) scores in Study 2. Individual ADSI symptoms were graded on a scale of 0 (none) to 3 (severe); sum provides total ADSI (maximum of 15); N = 29. *p < .001 versus baseline, †p < .05 versus baseline.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4318661&req=5

Figure 6: Improvement in Atopic Dermatitis Severity Index (ADSI) scores in Study 2. Individual ADSI symptoms were graded on a scale of 0 (none) to 3 (severe); sum provides total ADSI (maximum of 15); N = 29. *p < .001 versus baseline, †p < .05 versus baseline.

Mentions: Instant Therapy application significantly improved AD severity, decreasing total ADSI scores by 41.8% and 58.4% at Days 7 and 14, respectively (p < .001; Figure 6). Improvement in overall score was observed in 93.1% of subjects at Week 2. Treatment with Instant Therapy significantly improved the individual symptoms of AD, with the greatest improvements observed for pruritus (64.9%), erythema (54.0%), and lichenification (57.1%) at Day 14 (p < .001) and excoriation (73.6%) at Day 7 (p = .004; Figure 6). The visible improvement in the appearance of active lesions and the surrounding skin after 2 weeks of Instant Therapy can be seen in Figure 7; before and after photographs show examples of improvements in erythema, excoriation, lichenification, and lesion intensity after 2 weeks of treatment.


Efficacy and Tolerability of Steroid-Free, Over-the-Counter Treatment Formulations in Infants and Children With Atopic Dermatitis.

Weber TM, Herndon JH, Ewer M, Stephens TJ, Flick I, Filbry A, Neufang G, Schoelermann AM - J Dermatol Nurses Assoc (2015)

Improvement in Atopic Dermatitis Severity Index (ADSI) scores in Study 2. Individual ADSI symptoms were graded on a scale of 0 (none) to 3 (severe); sum provides total ADSI (maximum of 15); N = 29. *p < .001 versus baseline, †p < .05 versus baseline.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4318661&req=5

Figure 6: Improvement in Atopic Dermatitis Severity Index (ADSI) scores in Study 2. Individual ADSI symptoms were graded on a scale of 0 (none) to 3 (severe); sum provides total ADSI (maximum of 15); N = 29. *p < .001 versus baseline, †p < .05 versus baseline.
Mentions: Instant Therapy application significantly improved AD severity, decreasing total ADSI scores by 41.8% and 58.4% at Days 7 and 14, respectively (p < .001; Figure 6). Improvement in overall score was observed in 93.1% of subjects at Week 2. Treatment with Instant Therapy significantly improved the individual symptoms of AD, with the greatest improvements observed for pruritus (64.9%), erythema (54.0%), and lichenification (57.1%) at Day 14 (p < .001) and excoriation (73.6%) at Day 7 (p = .004; Figure 6). The visible improvement in the appearance of active lesions and the surrounding skin after 2 weeks of Instant Therapy can be seen in Figure 7; before and after photographs show examples of improvements in erythema, excoriation, lichenification, and lesion intensity after 2 weeks of treatment.

Bottom Line: Body Cream significantly improved skin hydration and reduced itching, burning/stinging, erythema, and tactile roughness.Both products were safe and well tolerated.These products provide steroid-free, nonprescription therapy for the maintenance and treatment of acute eczema and were proven effective and safe in infants as young as 3 months.

View Article: PubMed Central - PubMed

Affiliation: Teresa M. Weber, PhD, U.S. Research and Development, Beiersdorf, Inc., Wilton, CT.

ABSTRACT

Background: Two steroid-free, over-the-counter skin protectant products have been developed for the care and treatment of atopic dermatitis (AD)-Eucerin Eczema Relief Body Crème (Body Cream) for daily skin moisturization and Eucerin Eczema Relief Instant Therapy cream (Instant Therapy) for treatment of AD flare-ups. We tested the efficacy and tolerability of these formulations in infants and children with AD.

Methods: Study 1: Body Cream was applied twice daily to the lower legs of 64 children with a history of AD (aged 3 months to 12 years) for 14 days. Study 2: Instant Therapy was applied to active lesions and surrounding skin of 29 children (aged 3 months to 12 years) with active atopic lesions. Assessments were performed at baseline and Days 7 and 14. Symptoms were assessed using the Atopic Dermatitis Severity Index in Study 2.

Results: Body Cream significantly improved skin hydration and reduced itching, burning/stinging, erythema, and tactile roughness. Instant Therapy significantly improved skin hydration and AD symptoms, notably pruritus, erythema, and lichenification. Both products were safe and well tolerated.

Discussion: Body Cream and Instant Therapy were effective and well tolerated in the treatment of AD in children. These products provide steroid-free, nonprescription therapy for the maintenance and treatment of acute eczema and were proven effective and safe in infants as young as 3 months.

No MeSH data available.


Related in: MedlinePlus